Launching a clinical trial for a drug intended to treat severe asthma during a respiratory pandemic — particularly one that seems to hit people with some types of asthma particularly hard — could be a risky move.
But that’s precisely what Kinaset Therapeutics is planning to do early next year. After testing its drug in healthy people, the company hopes to start recruiting people with severe non-eosinophilic asthma — a subtype of asthma with inflammation that isn’t associated with high levels of one type of white blood cells. The company hopes its inhalable drug might help people with this type of asthma better control their condition.
The company, which first emerged in corporate filings this summer, officially announced its launch and a $40 million series A in a press release on Monday. Kinaset’s backers include Atlas Venture, Gimv, and 5AM Ventures.
About the Author Reprints
